This perspective highlights the importance of targeting triglyceride-rich lipoproteins to address residual cardiovascular risk in patients with atherogenic dyslipidemia, particularly those with obesity, insulin resistance, and type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
May address residual cardiovascular risk in diabetic dyslipidemia; leaves open confirmation in prospective trials.
Xiao et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: